MAIA MAIA Biotechnology, Inc.
Price Chart
Executive Summary
MAIA Biotechnology announced the pricing of a $30 million underwritten public offering of 20 million shares at $1.50 per share, with an additional 3 million shares available via an over-allotment option. The proceeds will fund clinical trials and general corporate purposes, with the offering led by healthcare-focused investors and existing shareholders. The stock is trading at a market cap of $84 million, implying significant dilution from the new shares.
Key Financial Metrics
Actionable Insight
Traders should monitor for downward pressure on the stock price due to significant dilution and typical post-offering weakness in small-cap biotech stocks. The lack of warrants is slightly positive, but the scale of dilution relative to market cap is substantial. Watch for insider participation or investor lock-ups as potential mitigating factors not disclosed here.
Key Facts
- MAIA is raising $30 million through an underwritten public offering of 20 million shares at $1.50 per share.
- Underwriters have a 45-day option to purchase up to 3 million additional shares to cover over-allotments.
- No warrants or other dilutive instruments were issued — this is a straightforward common stock offering.
- Proceeds will be used for clinical trials, working capital, and general corporate purposes.
- The offering is being made under a shelf registration (Form S-3) and is expected to close on March 4, 2026.
- Market cap is $84 million, meaning the gross proceeds represent ~35.7% of current equity value.
Financial Impact
Approximately $30 million in gross proceeds, with potential for $4.5 million more if over-allotment is exercised. Issuance of 20 million new shares represents ~28.6% dilution assuming 70 million prior shares outstanding (based on $84M market cap / $1.20 implied prior price).
Risk Factors
- High dilution relative to current market cap may pressure the stock price.
- No assurance that clinical trials funded by this offering will yield positive results.
- Biotech stocks often experience post-offering selloffs due to supply overhang and investor fatigue.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
11d ago
|
Press Release
| $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.30 (−9.09%) |
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $1.35 $1.43 | ▲ +5.93% | ▲ +6.62% | $1.30 (−3.70%) |
|
May 19, 2026
26d ago
|
DEFA14A
| $1.23 $1.29 | ▲ +4.88% | ▲ +3.84% | $1.30 (+5.69%) |
|
May 14, 2026
4w ago
|
8-K
| $1.26 $1.26 | · 0.00% | ▲ +0.06% | $1.30 (+3.17%) |
|
Apr 27, 2026
6w ago
|
DEFA14A
| $1.24 $1.25 | ▲ +0.81% | ▲ +1.29% | $1.30 (+4.84%) |
|
Apr 16, 2026
8w ago
|
8-K
| $1.33 $1.35 | ▲ +1.50% | ▲ +0.29% | $1.30 (−2.26%) |
|
Apr 8, 2026
9w ago
|
8-K
| $1.24 $1.20 | ▼ −3.23% | ▼ −3.80% | $1.30 (+4.84%) |
|
Apr 7, 2026
9w ago
|
DEFA14A
| $1.20 $1.24 | ▲ +3.33% | ▲ +0.79% | $1.30 (+8.33%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $1.53 $1.54 | ▲ +0.65% | ▲ +1.97% | $1.30 (−15.03%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $1.51 $1.56 | ▼ −3.31% | ▼ −2.55% | $1.30 (+13.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access